Dalpiciclib plus hormone therapy for early HR+/HER2- breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, randomized, open-label Phase 2 trial enrolling about 2,000 patients with hormone receptor–positive, HER2‑negative stage II–III breast cancer. Participants are randomized 1:1, stratified by nodal status, prior (neo)adjuvant chemotherapy, and clinical/pathologic stage, to receive dalpiciclib 125 mg for two years or dalpiciclib 100 mg for three years alongside standard endocrine therapy (letrozole, anastrozole, exemestane, or tamoxifen). Treatment continues until disease progression, intolerable side effects, withdrawal of consent, or investigator decision. The trial will track safety and efficacy outcomes to compare the two dosing strategies in the adjuvant setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Female aged 18 years or older with breast cancer who are postmenopausal or premenopausal/perimenopausal.
2. Patients with early-stage breast cancer whose HR status is positive and HER2 status is negative, as confirmed by histology (immunohistochemistry showing ER ≥10% and/or PR ≥10%, HER2 0-1+ or HER2 ++ but negative by FISH or CISH testing, with no amplification).
3. Patients with histologically confirmed invasive breast cancer at clinical/pathological stages II-III.

   Note: For stage IIA, N1 is required, or N0 with Grade 3 or Grade 2 tumors combined with high-risk factors such as Ki-67 ≥20% or positive genetic testing (including but not limited to high-risk results in the 21-gene test). If the patient has previously received neoadjuvant therapy, the clinical stage at the time before neoadjuvant therapy must meet the above criteria.
4. Patients who have previously received or not received neoadjuvant chemotherapy or adjuvant chemotherapy are eligible to enroll.
5. The time interval from surgery to enrollment must not exceed 12 months.
6. Patients who have received radiotherapy must have recovered from the acute effects of radiotherapy, and there must be at least 14 days of washout period from the end of radiotherapy to enrollment.
7. Patients who have previously received chemotherapy must have recovered from the acute adverse effects of chemotherapy before enrollment (\[CTCAE\] grade ≤1), except for hair loss or grade 2 peripheral neuropathy.There must be a washout period of at least 21 days between the last administration of chemotherapy and enrollment in the study. 8. The Eastern Cooperative Oncology Group performance status score must be 0-1. 9. The functions of major organs must meet the following requirements: a) Blood tests: neutrophils (ANC) ≥1.5×10\^9/L; platelet count (PLT) ≥90×10\^9/L; hemoglobin (Hb) ≥90 g/L. b) Blood biochemistry tests: total bilirubin (TBIL) ≤2.5×ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×ULN; alkaline phosphatase ≤2.5×ULN; blood urea nitrogen (BUN) and creatinine (Cr) ≤1.5×ULN. c) 12-lead electrocardiogram: QT interval corrected using the Fridericia method (QTcF) \< 470 ms in females (QTcF calculation formula: QTcF = QT/(RR\^1/3)). Participants must voluntarily agree to participate in the study, sign the informed consent form, demonstrate good compliance, and be willing to cooperate with follow-up assessments.

Exclusion Criteria:

1. Stage IV breast cancer or recurrent/metastatic breast cancer, or inflammatory breast cancer;
2. A history of any malignant tumor, or previous receipt of anti-tumor therapy or radiotherapy for any malignant tumor, excluding cured cases of cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma, etc.
3. Participating in other clinical trials simultaneously;
4. Received a blood transfusion within 2 weeks prior to enrollment, or received treatments such as colony-stimulating factors;
5. Individuals with a known history of allergy to any component of this medication;
6. A history of immunodeficiency, including a positive HIV test result, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
7. Any history of heart disease, including: (1) angina pectoris; (2) arrhythmias that require medical treatment or are clinically significant; (3) myocardial infarction; (4) heart failure; (5) any other heart disease deemed by the study investigators to be inappropriate for participation in this trial.
8. Pregnant or lactating female patients; 9. Any other circumstances in which the researchers deem the participant unsuitable for participating in this study.

Where it's running

• Fujian Cancer Hosptial
  Fuzhou, Fujian, China Recruiting
• West China Hospital of Sichuan University
  Chengdu, Sichuan, China Not yet recruiting

Study contacts

• Study coordinator: Chuangui Song, doctor
• Email: songcg1971@outlook.com
• Phone: 13960709993

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• AI-powered pre-treatment MRI to predict chemotherapy response in HR+/HER2- breast cancer

  This study tests whether AI analysis of baseline DCE-MRI can forecast which HR+/HER2- breast cancer patients will benefit most from neoadjuvant chemotherapy.

  Recruiting at 5 sites Fujian Cancer Hospital · Fuzhou, Fujian and 4 other locations · NCT07702708

• Benchmark and performance test for AI reading breast ultrasound images

  This project will test whether multimodal AI models can read breast ultrasound images to help classify normal, benign, and malignant findings for people who have had breast ultrasound.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07500428

• How local breast cancer treatments affect side effects and quality of life in Chinese patients

  This project will test how surgery and related treatments (chemotherapy, radiation, hormone or targeted therapy) affect side effects and daily quality of life for people with early-stage breast cancer in China.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality and 2 other locations · NCT07010939

• Understanding breast cancer risk factors and outcomes in Florida

  This study is trying to understand the different risk factors and outcomes of breast cancer in men and women in Florida by collecting samples and survey information from new patients at breast clinics.

  Recruiting at 2 sites Memorial Sloan Kettering Cancer Center · Los Angeles, California and 2 other locations · NCT06780176

• 68Ga-FAPI-46 versus 18F-FDG PET imaging in ER-positive breast cancer

  This test compares whether 68Ga-FAPI-46 PET scans find more cancer spread than standard 18F-FDG PET scans in people with ER-positive breast cancer who need staging.

  Recruiting Phase 2 Maastricht University Medical Center · Maastricht · NCT06335069

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.